A Somatostatin Receptor Subtype-3 (SST3) Peptide Agonist Shows Antitumor Effects in Experimental Models of Nonfunctioning Pituitary TumorsMari C. Vázquez‐Borrego, Raúl M. Luque, Vandana Gupta et al.|Clinical Cancer Research|2019Cited by 52
Biguanides Exert Antitumoral Actions in Pituitary Tumor Cells Through AMPK-Dependent and -Independent MechanismsMari C. Vázquez‐Borrego, Raúl M. Luque, Antonio C. Fuentes-Fayos et al.|The Journal of Clinical Endocrinology & Metabolism|2019Cited by 36
Biguanides exert antitumoral actions in pituitary tumor cells through AMPK-dependent and -independent mechanismsAura D. Herrera‐Martínez, Raúl M. Luque, María Ángeles Gálvez-Moreno et al.|Endocrine Abstracts|2019Cited by 1
Data from A Somatostatin Receptor Subtype-3 (SST<sub>3</sub>) Peptide Agonist Shows Antitumor Effects in Experimental Models of Nonfunctioning Pituitary TumorsMari C. Vázquez‐Borrego, Raúl M. Luque, Vandana Gupta et al.|Unknown|2023Cited by 0
Figure S2 from A Somatostatin Receptor Subtype-3 (SST<sub>3</sub>) Peptide Agonist Shows Antitumor Effects in Experimental Models of Nonfunctioning Pituitary TumorsMari C. Vázquez‐Borrego, Raúl M. Luque, Vandana Gupta et al.|Unknown|2023Cited by 0